ECSP088081A - Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente - Google Patents

Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente

Info

Publication number
ECSP088081A
ECSP088081A EC2008008081A ECSP088081A ECSP088081A EC SP088081 A ECSP088081 A EC SP088081A EC 2008008081 A EC2008008081 A EC 2008008081A EC SP088081 A ECSP088081 A EC SP088081A EC SP088081 A ECSP088081 A EC SP088081A
Authority
EC
Ecuador
Prior art keywords
therapeutic antibody
detection
diana
ancient
absence
Prior art date
Application number
EC2008008081A
Other languages
English (en)
Inventor
Helmut Lenz
Werner Scheuer
Martina Thier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088081A publication Critical patent/ECSP088081A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención está relacionada con el campo de los anticuerpos terapéuticos. La invención especialmente está relacionada con un método para la detección del antígeno diana de un anticuerpo terapéutico en una muestra que consiste en los siguientes pasos: a) proporcionar la muestra a analizar, b) incubar dicha muestra con dicho anticuerpo terapéutico bajo las condiciones apropiadas para unir dicho anticuerpo terapéutico a dicho antígeno diana, de manera que se forma un complejo de antígeno diana-anticuerpo terapéutico y c) detectar el complejo formado en (b).
EC2008008081A 2005-07-06 2008-01-04 Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente ECSP088081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
ECSP088081A true ECSP088081A (es) 2008-02-20

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008081A ECSP088081A (es) 2005-07-06 2008-01-04 Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente

Country Status (19)

Country Link
US (1) US20070009976A1 (es)
EP (2) EP2194380A3 (es)
JP (1) JP2008545145A (es)
KR (1) KR20080016939A (es)
AR (1) AR053948A1 (es)
AU (1) AU2006265275A1 (es)
BR (1) BRPI0612591A2 (es)
CA (1) CA2613187A1 (es)
CR (1) CR9635A (es)
EC (1) ECSP088081A (es)
IL (1) IL188317A0 (es)
MA (1) MA29730B1 (es)
MX (1) MX2008000277A (es)
MY (1) MY157955A (es)
NO (1) NO20076662L (es)
NZ (1) NZ564471A (es)
RU (1) RU2008103608A (es)
TW (1) TWI312864B (es)
WO (1) WO2007003420A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1282443E (pt) * 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
KR101134208B1 (ko) 2004-10-01 2012-04-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 촬상 장치 및 그 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
WO2007092581A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical aberrations
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
CA2269204C (en) 1996-10-18 2012-01-24 Genentech, Inc. Anti-erbb2 antibodies
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
EP2263691B1 (en) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)

Also Published As

Publication number Publication date
MA29730B1 (fr) 2008-09-01
CR9635A (es) 2008-02-20
EP2194380A3 (en) 2010-07-14
BRPI0612591A2 (pt) 2010-11-23
RU2008103608A (ru) 2009-08-20
TWI312864B (en) 2009-08-01
MY157955A (en) 2016-08-30
AU2006265275A1 (en) 2007-01-11
EP2194380A2 (en) 2010-06-09
JP2008545145A (ja) 2008-12-11
US20070009976A1 (en) 2007-01-11
EP1902315A1 (en) 2008-03-26
MX2008000277A (es) 2008-03-24
AR053948A1 (es) 2007-05-23
NO20076662L (no) 2008-04-03
KR20080016939A (ko) 2008-02-22
WO2007003420A1 (en) 2007-01-11
NZ564471A (en) 2010-04-30
CA2613187A1 (en) 2007-01-11
TW200741203A (en) 2007-11-01
IL188317A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
ECSP088081A (es) Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente
EP4249605A3 (en) Methods for analyte detection
MX362075B (es) Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
EP4273551A3 (en) Multiplexed total antibody and antibody-conjugated drug quantification assay
HK1202154A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
HK1202157A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
NZ609824A (en) Immunochromatography devices, methods and kits
MX358772B (es) Metodo para detectar cancer.
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
MX2015013596A (es) Metodos, dispositivos y sistemas para analisis de muestras.
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
TW200801202A (en) Alpha-enolase specific antibody and method of use
DK1989544T3 (da) T-celle-testmetode
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
MX2009012048A (es) Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato.
WO2011008831A3 (en) Mass tags for spectrometric analysis of immunoglobulins
BR112018017336A2 (pt) método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão
PE20130526A1 (es) Componentes de la pared de celulas de levadura y deteccion de los mismos
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
EA201691168A1 (ru) Способы исследования бета-глюкана
ES2527703B1 (es) Inmunosensor electroquímico para la determinación cuantitativa de la micotoxina fb1
FR2968767B1 (fr) Procede et coffret pour le diagnostic in vitro du cancer de la prostate
CL2009001907A1 (es) Metodo de deteccion precoz de cancer gastrico que comprende detectar la presencia de marcadores especificos de cancer gastrico en muestras de plasma.
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto